developer_or_researcher,country_name,ioc_country_code,treatment_vs_vaccine,product_category,stage_of_development,date_last_updated,anticipated_next_steps,product_description,clinical_trials,funder,published_results,clinical_trials_for_other_diseases_or_related_use,fda_approved_indications,sources
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",South Korea,KOR,Vaccine,DNA-based,Phase I/II,11/16/2020,Phase I/II study: Phase I began end of June 2020; Animal study results announced August 2020,DNA; (GX-19),NCT04445389,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific,China,CHN,Vaccine,DNA-based,Phase I/II,9/28/2020,"FDA partial clinical hold for planned Phase II/ III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020",DNA; (INO-4800) plasmid vaccine with electroporation,"NCT04336410, NCT04447781",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx),Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech,Japan,JPN,Vaccine,DNA-based,Phase I/II,11/16/2020,"Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021",DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant,"NCT04463472, NCT04527081",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Zydus Cadila Healthcare Limited,India,IND,Vaccine,DNA-based,Phase I/II,9/23/2020,"Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020",DNA; (ZyCoV-D) plasmid vaccine,CTRI/2020/07/026352,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Symvivo,Canada,CAN,Vaccine,DNA-based,Phase I,11/2/2020,Phase I dosed November 2020,DNA; bacTRL-Spike,NCT04334980,National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet,Australia,AUS,Vaccine,DNA-based,Pre-clinical,11/16/2020,Phase I expected to begin Q4 2020,DNA; (COVIGEN) needle-free delivery,,Australian Government Medical Research Future Fund (MRFF),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Chula Vaccine Research Center,Thailand,THA,Vaccine,DNA-based,Pre-clinical,9/23/2020,Unknown,DNA with electroporation,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK),Turkey,TUR,Vaccine,DNA-based,Pre-clinical,9/23/2020,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Entos Pharmaceuticals/ Cytiva,Canada,CAN,Vaccine,DNA-based,Pre-clinical,11/16/2020,Phase I/II expected to begin November 2020,DNA; (Covigenix),NCT04591184,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Globe Biotech Limited, Bangladesh",Bangladesh,BAN,Vaccine,DNA-based,Pre-clinical,11/9/2020,Unknown,DNA plasmid vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Immunomic Therapeutics/ EpiVax/ PharmaJet,United States,USA,Vaccine,DNA-based,Pre-clinical,Prior to 4/20/2020,Unknown,"DNA; plasmid vaccine, needle-free delivery",,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Mediphage Bioceuticals/ University of Waterloo/ Lambton College,Canada,CAN,Vaccine,DNA-based,Pre-clinical,9/23/2020,Unknown,DNA; msDNA-VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National
  Research Centre, Egypt",Egypt,EGY,Vaccine,DNA-based,Pre-clinical,6/30/2020,Unknown,"DNA; plasmid vaccine S, S1, S2, RBD & N",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National Institute of Chemistry, Slovenia",Slovenia,SLO,Vaccine,DNA-based,Pre-clinical,11/9/2020,Unknown,"Plasmid DNA, nanostructured RBD",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
OncoSec Medical Incorporated / Providence Cancer Institute,United States,USA,Vaccine,DNA-based,Pre-clinical,11/18/2020,Phase I expected to begin December 2020,"(CORVax12), IL-12 expression platform + “S” glycoprotein ",NCT04627675,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm,Sweden,SWE,Vaccine,DNA-based,Pre-clinical,9/23/2020,Phase I expected to begin in 2020,DNA with electroporation,,European Commission (Horizon 2020 Program),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Scancell/ University of Nottingham/ Nottingham Trent University,Sweden,SWE,Vaccine,DNA-based,Pre-clinical,9/23/2020,Phase I to start in Q1 2021,DNA; plasmid vaccine RBD&N,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Statens Serum Institute, Denmark",Denmark,DEN,Vaccine,DNA-based,Pre-clinical,11/16/2020,Phase I is expected to start in late 2020 or early 2021,DNA; (CoVAXIX) plasmid vaccine,,Folketing's Finance Committee,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Takis/ Applied DNA Sciences/ Evvivax,United States,USA,Vaccine,DNA-based,Pre-clinical,9/23/2020,Pre-clinical results released in May and July 2020; Phase I expected to begin fall 2020,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Cambridge/ DIOSynVax/ PharmaJet,Great Britain,GBR,Vaccine,DNA-based,Pre-clinical,10/28/2020,Phase I expected to begin late fall 2020 or early 2021,DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems,,Innovate UK,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Beijing Institute of Biological Products/ Sinopharm,China,CHN,Vaccine,Inactivated virus,Phase III,12/18/2020,"Bahrain National Health Regulatory Authority (NHRA) ""approved"" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced ""official registration"" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)","Inactivated, (BBIBP-CorV)","ChiCTR2000032459, ChiCTR2000034780, NCT04560881",Unknown,The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology,India,IND,Vaccine,Inactivated virus,Phase III,12/1/2020,"Phase III dosed November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020",Inactivated; whole-virion (COVAXIN) (BBV152),"CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Sinovac/ Instituto Butantan/ Bio Farma,Brazil,BRA,Vaccine,Inactivated virus,Phase III,12/8/2020,"Phase III trial interim results expected to be released early December 2020; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for ""emergency use"" in China (Aug 2020)",Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc),"NCT04352608, NCT04383574, NCT04456595, NCT04508075, NCT04551547, NCT04582344, 669/UN6.KEP/EC/2020",Unknown,"Sinovac (http://www.sinovac.com/?optionid=754&auto_id=904), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1), http://www.sinovac.com/?optionid=754&auto_id=910, The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext)",Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Wuhan Institute of Biological Products/ Sinopharm,China,CHN,Vaccine,Inactivated virus,Phase III,12/8/2020,"Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Inactivated," ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000 ",Unknown,"(https://www.cnbg.com.cn/content/details_12_5545.html), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2769612)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Institute of Medical Biology, Chinese Academy of Medical Sciences",China,CHN,Vaccine,Inactivated virus,Phase II,12/14/2020,"Phase III expected to begin December 2020; Phase II began June 2020; Phase I began May 2020, results released October 2020",Inactivated,"NCT04412538, NCT04470609",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Kazakhstan,KAZ,Vaccine,Inactivated virus,Phase I/II,9/17/2020,Phase I/II began September 2020,"Inactivated, QAZCOVID-IN®",NCT04530357,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Erciyes University,Turkey,TUR,Vaccine,Inactivated virus,Phase I,12/15/2020,"Phase II expected to begin by end of December 2020; Phase I began November 2020, completed on December 14, 2020",Inactivated; (ERUCOV-VAC),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Beijing Minhai Biotechnology Co., Ltd.",China,CHN,Vaccine,Inactivated virus,Pre-clinical,11/3/2020,Phase II expected to begin recruiting end of October 2020; Phase I expected to begin recruiting early October 2020,Inactivated,"ChiCTR2000038804, ChiCTR2000039462 ",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Government
  Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH",Thailand,THA,Vaccine,Inactivated virus,Pre-clinical,11/9/2020,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Institute
  Butantan (Brazil) / Dynavax / PATH",Brazil,BRA,Vaccine,Inactivated virus,Pre-clinical,11/9/2020,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH,Vietnam,VIE,Vaccine,Inactivated virus,Pre-clinical,11/9/2020,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
KM Biologics,Japan,JAP,Vaccine,Inactivated virus,Pre-clinical,7/9/2020,Unknown,Inactivated (inactivated + alum),,Unknown,,"Same platform as vaccine candidates for JE, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Kocak Farma Ilac ve Kimya San. A.S.,Turkey,TUR,Vaccine,Inactivated virus,Pre-clinical,11/9/2020,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National Research Centre, Egypt",Egypt,EGY,Vaccine,Inactivated virus,Pre-clinical,6/30/2020,Unknown,Inactivated whole virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Osaka University / BIKEN / NIBIOHN,Japan,JAP,Vaccine,Inactivated virus,Pre-clinical,Prior to 4/20/2020,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Selcuk University,Turkey,TUR,Vaccine,Inactivated virus,Pre-clinical,9/23/2020,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Sinovac/ Dynavax,China,CHN,Vaccine,Inactivated virus,Pre-clinical,4/28/2020,Unknown,Inactivated + adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Valneva/ Dynavax,United States,USA,Vaccine,Inactivated virus,Pre-clinical,7/8/2020,Unknown,"Inactivated (Inactivated + CpG 1018), VLA2001",,Unknown,,Same platform as vaccine candidates for Japanese Encephalitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Codagenix / Serum Institute of India,India,IND,Vaccine,Live attenuated virus,Pre-clinical,12/21/2020,"Phase I recruitment began December 2020, dosing expected to begin January 2021",Codon deoptimized live attenuated virus,,Unknown,,"Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Indian Immunologicals Ltd/ Griffith University,India,IND,Vaccine,Live attenuated virus,Pre-clinical,4/28/2020,Unknown,Codon deoptimized live attenuated virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Turkey,TUR,Vaccine,Live attenuated virus,Pre-clinical,7/9/2020,Unknown,Codon deoptimized live attenuated vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Meissa Vaccines ,United States,USA,Vaccine,Live attenuated virus,Pre-clinical,7/2/2020,Start Phase 1 beginning of 2021,MV-014-210,,Unknown,,Same platform as vaccine candidates for RSV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax,Russia,RUS,Vaccine,Non-replicating viral vector,Phase III,12/18/2020,"Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission ""approved the use of the vaccine by the military"" in June 2020",Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV),"ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04566770, NCT04568811",Unknown,"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)",Same platform as vaccine candidates for EBOV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Gamaleya Research Institute,Russia,RUS,Vaccine,Non-replicating viral vector,Phase III,12/18/2020,"Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health ""registered"" vaccine in August 2020","Adeno-based, Gam-COVID-Vac Lyo (Sputnik V)","NCT04437875, NCT04436471, NCT04530396, NCT04564716, NCT04587219",Russian Direct Investment Fund (RDIF),"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data-analysis-of-the-sputnik-v-vaccine-against-covid-19-phase-iii-clinical-trials-/), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM),United States,USA,Vaccine,Non-replicating viral vector,Phase III,12/8/2020,"Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2 trial); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020","Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)","NCT04436276, NCT04505722",Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Ebola, HIV, RSV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA",Great Britain,GBR,Vaccine,Non-replicating viral vector,Phase III,12/8/2020,"Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020",Non-replicating viral vector; AZD 1222 (formerly ChAdOx1),""" CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, PACTR202005681895696, PACTR202006922165132""","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance","The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext), AstraZeneca (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/)","Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ImmunityBio/ NantKwest,United States,USA,Vaccine,Non-replicating viral vector,Phase I,12/15/2020,"Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I dosed October 2020; Selected for US Operation Warp Speed in May 2020","Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid",NCT04591717,Unknown,,"Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani,Italy,ITA,Vaccine,Non-replicating viral vector,Phase I,12/15/2020,"Phase I began August 2020, preliminary results announced November 2020; Phase II/III trial expected to begin in the coming months",Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2),"EudraCT 2020-002835-31, NCT04528641",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vaxart/ Emergent BioSolutions,United States,USA,Vaccine,Non-replicating viral vector,Phase I,10/13/2020,"Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study expected in October 2020","Non-replicating viral vector; Oral Vaccine
 platform",NCT04563702,Unknown,,"Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Altimmune / University of Alabama at Birmingham,United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,Prior to 4/20/2020,Phase I trial to begin Q3 2020,"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Ankara University,Turkey,TUR,Vaccine,Non-replicating viral vector,Pre-clinical,7/9/2020,Unknown,Adenovirus-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Bharat Biotech/ Thomas Jefferson University,India,IND,Vaccine,Non-replicating viral vector,Pre-clinical,11/16/2020,Unknown,Recombinant deactivated rabies virus containing S1; (CoraVax),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",China,CHN,Vaccine,Non-replicating viral vector,Pre-clinical,11/2/2020,Phase I recruitment began end of September 2020,Ad5-nCoV,NCT04552366,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Spain,ESP,Vaccine,Non-replicating viral vector,Pre-clinical,Prior to 4/20/2020,Unknown,"Non-replicating viral vector, MVA expressing structural proteins",,Unknown,,"Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"City of
  Hope Medical Center",United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,11/24/2020,Phase I expected to begin November 2020,MVA-based SARS-CoV-2 vaccine; (COH04S1),NCT04639466,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Erciyes University,Turkey,TUR,Vaccine,Non-replicating viral vector,Pre-clinical,8/3/2020,Unknown,Adeno5-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
GeoVax / BravoVax,United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,Prior to 4/20/2020,Unknown,Non-replicating viral vector; MVA encoded VLP,,Unknown,,"Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich,Germany,GER,Vaccine,Non-replicating viral vector,Pre-clinical,10/20/2020,Phase I expected to be dosed mid-October 2020,Non-replicating viral vector; MVA-S encoded,NCT04569383,Unknown,,Same platform as vaccine candidates for many pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Globe Biotech Limited, Bangladesh",Bangladesh,BAN,Vaccine,Non-replicating viral vector,Pre-clinical,11/9/2020,Unknown,Adenovirus Type 5 Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Greffex,United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,Prior to 4/20/2020,Unknown,Non-replicating viral vector; Ad5 S (GREVAX™ platform),,Unknown,,"Same platform as vaccine candidates for MERS
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ID Pharma,Japan,JAP,Vaccine,Non-replicating viral vector,Pre-clinical,7/9/2020,Unknown,Sendai virus vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"IDIBAPS- Hospital Clinic, Spain",Spain,ESP,Vaccine,Non-replicating viral vector,Pre-clinical,6/1/2020,Unknown,MVA-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Institut
  Pasteur/ TheraVectys",France,FRA,Vaccine,Non-replicating viral vector,Pre-clinical,9/2/2020,Animal study results released July 2020,Intranasal lentiviral vector vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Massachusetts Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,6/2/2020,Phase 1 to begin second half of 2020,"AAVCOVID, Adeno-associated viral vector (AAV), spike protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National
  Research Centre, Egypt",Egypt,EGY,Vaccine,Non-replicating viral vector,Pre-clinical,6/30/2020,Unknown,Influenza A H1N1 vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Thailand,THA,Vaccine,Non-replicating viral vector,Pre-clinical,6/1/2020,Unknown,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Stabilitech Biopharma Ltd,Great Britain,GBR,Vaccine,Non-replicating viral vector,Pre-clinical,5/4/2020,Unknown,Oral Ad5 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Georgia/ University of Iowa,United States,USA,Vaccine,Non-replicating viral vector,Pre-clinical,4/28/2020,Unknown,Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Helsinki/ University of Eastern Finland,Finland,FIN,Vaccine,Non-replicating viral vector,Pre-clinical,11/9/2020,Unknown,Ad 5 vector for intranasal administration,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Valo Therapeutics Ltd,Finland,FIN,Vaccine,Non-replicating viral vector,Pre-clinical,5/4/2020,Unknown,Adenovirus-based + HLA-matched peptides (Pan-Corona),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo,United States,USA,Vaccine,Protein subunit,Phase III,11/16/2020,"FDA granted Fast Track Designation on 11/9/2020; Phase III expected to begin in the US by end of November 2020; Phase III dosed in the UK in October 2020, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020",Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373),"NCT04368988, NCT04533399, EudraCT 2020-004123-16, NCT04583995",Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2026920)","Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",China,CHN,Vaccine,Protein subunit,Phase II,9/28/2020,Phase II began July 2020; Received approval to launch clinical trials in China in June 2020; Phase I preliminary results expected in September 2020,Adjuvanted recombinant protein (RBD-Dimer),"NCT04445194, NCT04466085, NCT04550351",Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,Protein subunit,Phase I/II,10/15/2020,Received early approval for use in Russia in October 2020; Phase I/II trial began end of July 2020,"Peptide vaccine, EpiVacCorona",NCT04527575,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Instituto Finlay de Vacunas,Cuba,CUB,Vaccine,Protein subunit,Phase I/II,11/3/2020,Phase I/II began August 2020,RBD + Adjuvant (FINLAY-FR-1),IFV/COR/04 (RPCEC00000332),Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Sanofi Pasteur/ GSK,France,FRA,Vaccine,Protein subunit,Phase I/II,12/14/2020,Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020,"Protein subunit; S protein, baculovirus production",NCT04537208,Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD),,"Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Adimmune
  Corporation",Chinese Taipei,TPE,Vaccine,Protein subunit,Phase I,9/2/2020,Phase I began end of August 2020; Phase II expected to begin November 2020,"Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)",NCT04522089,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Clover Biopharmaceuticals Inc./ GSK/ Dynavax,United States,USA,Vaccine,Protein subunit,Phase I,12/8/2020,"Phase I trial data released on 12/4/2020; Phase II/III trial (with GSK adjuvant) expected to begin in December 2020; Phase II/III trial (with Dynavax adjuvant) expected to begin during first half of 2021; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future; Phase II/III expected to begin before the end of 2020","Protein subunit, native like trimeric subunit spike protein",NCT04405908,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for HIV, RSV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Covaxx/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia,United States,USA,Vaccine,Protein subunit,Phase I,11/3/2020,Phase I began September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US,S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612,NCT04545749,Ministry of Health and Welfare in Taiwan,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,United States,USA,Vaccine,Protein subunit,Phase I,12/15/2020,Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020,MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018,NCT04487210,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies,Australia,AUS,Vaccine,Protein subunit,Phase I,10/1/2020,Phase I trial began July 2020,Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19),NCT04453852,Innovate UK/ Australian Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"West China Hospital, Sichuan University",China,CHN,Vaccine,Protein subunit,Phase I,9/10/2020,Phase I began end of August 2020; Animal study data published July 2020,"RBD (baculovirus production
expressed in Sf9 cells)",ChiCTR2000037518,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
AdaptVac (PREVENT-nCoV consortium),Denmark,DEN,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Unknown,"Protein subunit, capsid-like particle (CLP)",,European Commission (Horizon 2020 Program),,Same platform as vaccine candidates for HPV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
AJ Vaccines,Denmark,DEN,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
AnyGo Technology,China,CHN,Vaccine,Protein subunit,Pre-clinical,5/4/2020,Unknown,"Protein subunit, recombinant S1-Fc fusion protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Applied Biotechnology Institute, Inc.",United States,USA,Vaccine,Protein subunit,Pre-clinical,5/12/2020,Unknown,"Orally delivered, heat stable subunit",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Axon Neuroscience SE,Slovakia,SVK,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Pre-clinical results released September 2020,Peptides derived from Spike protein; (ACvac1),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Baiya Phytopharm/ Chula Vaccine Research Center,Thailand,THA,Vaccine,Protein subunit,Pre-clinical,6/18/2020,Unknown,Plant-based subunit (RBD-Fc + Adjuvant),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Baylor College of Medicine,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; S1 or RBD protein,,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Biological E Ltd,India,IND,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; adjuvanted protein subunit (RBD),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
BiOMVis Srl/ University of Trento,Italy,ITA,Vaccine,Protein subunit,Pre-clinical,5/12/2020,Unknown,OMV-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Bogazici University,Turkey,TUR,Vaccine,Protein subunit,Pre-clinical,7/9/2020,Unknown,Peptide + novel adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Chulalongkorn University/ GPO, Thailand",Thailand,THA,Vaccine,Protein subunit,Pre-clinical,6/1/2020,Unknown,RBD protein fused with Fc of IgG + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
EpiVax,United States,USA,Vaccine,Protein subunit,Pre-clinical,5/27/2020,Unknown,Protein subunit EPV-CoV-19,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
EpiVax / University of Georgia,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; S protein,,Unknown,,Same platform as vaccine candidates for Inf H7N9,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ExpreS2ion,Sweden,SWE,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, drosophila S2 insect cell expression system VLPs",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Peru,PER,Vaccine,Protein subunit,Pre-clinical,8/28/2020,Unknown,RBD protein (baculovirus production) + FAR-Squalene adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,Protein subunit,Pre-clinical,8/31/2020,Unknown,Subunit vaccine,,Unknown,,Same platform as vaccine candidates for Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Flow Pharma,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, peptide",,Unknown,,"Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Generex / EpiVax,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; Ii-Key peptide,,Unknown,,"Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,United States,USA,Vaccine,Protein subunit,Pre-clinical,8/13/2020,Animal data released August 2020,Protein subunit (gp-96 backbone),,Unknown,,"Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Nigeria,NGR,Vaccine,Protein subunit,Pre-clinical,6/30/2020,Unknown,Subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
iBio / CC-Pharming,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit; Subunit protein, plant produced",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ImmunoPrecise/ LiteVax BV,Netherlands,NED,Vaccine,Protein subunit,Pre-clinical,7/15/2020,Unknown,Spike-based (epitope screening),,TRANSVAC2,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Canada,CAN,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Phase I/II expected to begin by end of 2020,"Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",,"National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)",,"Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
InnoMedica,Switzerland,SUI,Vaccine,Protein subunit,Pre-clinical,7/9/2020,Unknown,"Protein subunit, TaliCoVax19 ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Innovax / Xiamen University / GSK,China,CHN,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; COVID-19 XWG-03 truncated Spike proteins,,Unknown,,"Same platform as vaccine candidates for HPV  
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Instituto Finlay de Vacunas,Cuba,CUB,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Phase I expected to begin November 2020,rRBD produced in CHO-cell chemically conjugate to tetanus toxoid,IFV/COR/06 (RPCEC00000340),Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Intravacc/Epivax,United States,USA,Vaccine,Protein subunit,Pre-clinical,5/19/2020,Unknown,Outer Membrane Vesicle (OMV)-peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Intravacc/Epivax,United States,USA,Vaccine,Protein subunit,Pre-clinical,6/12/2020,Unknown,Outer Membrane Vesicle (OMV)-subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Izmir Biomedicine and Genome Center,Turkey,TUR,Vaccine,Protein subunit,Pre-clinical,7/9/2020,Unknown,Recombinant S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Kazakh National Agrarian University,Kazakhstan,KAZ,Vaccine,Protein subunit,Pre-clinical,11/10/2020,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections",Kazakhstan,KAZ,Vaccine,Protein subunit,Pre-clinical,11/10/2020,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Kentucky BioProcessing (British American Tobacco),United States,USA,Vaccine,Protein subunit,Pre-clinical,9/28/2020,Phase I/II expected to begin mid-November 2020,"RBD-based, (KBP-COVID-19)",NCT04473690,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"LakePharma, Inc.",United States,USA,Vaccine,Protein subunit,Pre-clinical,5/4/2020,Unknown,"Protein subunit, nanoparticle vaccine",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Lomonosov Moscow State University,Russia,RUS,Vaccine,Protein subunit,Pre-clinical,5/27/2020,Unknown,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Max-Planck Institute of Colloids and Interfaces,Germany,GER,Vaccine,Protein subunit,Pre-clinical,11/10/2020,Unknown,Recombinant S protein,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
MIGAL Galilee Research Institute,Israel,ISR,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; oral E. coli-based protein expression system of S and N proteins,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"MOGAM Institute for Biomedical Research, GC Pharma",South Korea,KOR,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Mynvax,India,IND,Vaccine,Protein subunit,Pre-clinical,7/15/2020,Unknown,RBD-protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National
  Research Centre, Egypt",Egypt,EGY,Vaccine,Protein subunit,Pre-clinical,6/30/2020,Unknown,"Protein Subunit S, N, M & S1 protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"National Institute of Infectious Disease, Japan",Japan,JAP,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, S protein + adjuvant",,Unknown,,Same platform as vaccine candidates for Influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Neo7Logix,United States,USA,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Unknown,Peptides,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Neovii/Tel Aviv University,Israel,ISR,Vaccine,Protein subunit,Pre-clinical,5/19/2020,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Ohio State University/ Kazakh National Agrarian University,Kazakhstan,KAZ,Vaccine,Protein subunit,Pre-clinical,11/10/2020,Unknown,RBD protein delivered in mannose-conjugated chitosan nanoparticle,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
OncoGen,Romania,ROU,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Japan,JAP,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, VLP-recombinant protein + adjuvant",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
PDS Biotechnology,United States,USA,Vaccine,Protein subunit,Pre-clinical,6/2/2020,Unknown,PDS-0203; Versamune T-cell activating technology,,Unknown,,"Same platform as vaccines against cancers, HBV, influenza, and tuberculosis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Quadram Institute Biosciences,Great Britain,GBR,Vaccine,Protein subunit,Pre-clinical,5/12/2020,Unknown,OMV-based vaccine,,Unknown,,"Same platform as vaccine candidates for Flu A, plaque
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Research
  Institute for Biological Safety Problems, Rep of Kazakhstan",Kazakhstan,KAZ,Vaccine,Protein subunit,Pre-clinical,8/3/2020,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Soligenix/ University of Hawaii at Mānoa,United States,USA,Vaccine,Protein subunit,Pre-clinical,8/27/2020,Pre-clinical testing results released in July 2020,CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant,,"Soligenix, Inc. ",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Sorrento Therapeutics,United States,USA,Vaccine,Protein subunit,Pre-clinical,8/17/2020,Animal study results released July 2020,Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
St. Petersburg Scientific Research Institute of Vaccines and Serums,Russia,RUS,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Tampere University,Finland,FIN,Vaccine,Protein subunit,Pre-clinical,11/10/2020,Unknown,Recombinant S protein produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
UMN Pharma (Shionogi),Japan,JAP,Vaccine,Protein subunit,Pre-clinical,5/10/2020,Phase I to start by end of 2020,"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",,Japan Agency for Medical Research and Development,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University Hospital Tuebingen,Germany,GER,Vaccine,Protein subunit,Pre-clinical,9/18/2020,Phase I expected to begin September 2020,SARS-CoV-2 HLA-DR peptides,NCT04546841,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Alberta,Canada,CAN,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; spike based,,Unknown,,Same platform as vaccine candidates for Hepatitis C,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"University of California, San Diego",United States,USA,Vaccine,Protein subunit,Pre-clinical,4/28/2020,Unknown,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch,,National Science Foundation (Rapid Response Research [RAPID] grant),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Pittsburgh,United States,USA,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Phase I to start as early as June 2020,"PittCoVacc, Protein subunit, microneedle arrays S1 subunit",,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"University of San Martin and CONICET, Argentina",Argentina,ARG,Vaccine,Protein subunit,Pre-clinical,6/12/2020,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Virginia,United States,USA,Vaccine,Protein subunit,Pre-clinical,7/8/2020,Unknown,S subunit intranasal liposomal formulation with GLA/3M052 adjs.,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vabiotech,Vietnam,VIE,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Unknown,"Protein subunit, recombinant S protein in IC-BEVS  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vaxil Bio,Canada,CAN,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Unknown,Protein subunit; peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Verndari/ University of California, Davis",United States,USA,Vaccine,Protein subunit,Pre-clinical,8/27/2020,"Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020",Spike protein; VaxiPatch microneedle array dermal patch,,"Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)",,Same platform as vaccines against influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"VIDO-InterVac, University of Saskatchewan",Canada,CAN,Vaccine,Protein subunit,Pre-clinical,Prior to 4/20/2020,Animal testing results expected in April 2020,"Protein subunit, adjuvanted microsphere peptide",,The Government of Saskatchewan and the Canadian Federal Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
WRAIR / USAMRIID,United States,USA,Vaccine,Protein subunit,Pre-clinical,11/16/2020,Phase I expected to begin late 2020,Protein subunit; S protein (SpFN),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Yisheng Biopharma,China,CHN,Vaccine,Protein subunit,Pre-clinical,5/4/2020,Unknown,"Protein subunit, recombinant protein  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Institut Pasteur/ Themis/ University of Pittsburgh CVR/ Merck Sharp & Dohme,France,FRA,Vaccine,Replicating viral vector,Phase I/II,9/17/2020,Phase I/II began September 2020; Animal testing began April 2020,Replicating viral vector; measles vector (V591); formerly (TMV-083),"NCT04497298, NCT04498247",Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Aurobindo,India,IND,Vaccine,Replicating viral vector,Pre-clinical,7/15/2020,Unknown,VSV-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
BIOCAD / IEM,Russia,RUS,Vaccine,Replicating viral vector,Pre-clinical,Prior to 4/20/2020,Unknown,"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
DZIF - German Center for Infection Research/ CanVirex AG,Germany,GER,Vaccine,Replicating viral vector,Pre-clinical,6/30/2020,Unknown,"Measles virus (S, N targets)",,Unknown,,"Same platform as vaccine candidates for Zika, H7N9, CHIKV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Farmacológicos Veterinarios SAC (FARVET SAC)/ Universidad Peruana Cayetano Heredia (UPCH),Peru,PER,Vaccine,Replicating viral vector,Pre-clinical,11/9/2020,Unknown,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,Replicating viral vector,Pre-clinical,8/31/2020,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,Replicating viral vector,Pre-clinical,8/31/2020,Unknown,Replicating viral vector; VSV vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,Replicating viral vector,Pre-clinical,8/31/2020,Unknown,"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Fundacao Oswaldo Cruz and Instituto Buntantan,Brazil,BRA,Vaccine,Replicating viral vector,Pre-clinical,5/27/2020,Unknown,Attenuated Influenza expressing an antigenic portion of the Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
IAVI/ Merck,United States,USA,Vaccine,Replicating viral vector,Pre-clinical,10/28/2020,Phase I expected to begin in late October 2020; Selected for US Operation Warp Speed in April 2020; clinical studies to start in 2020,"Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein; (V590)",NCT04569786,Biomedical Advanced Research and Development Authority (BARDA); Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD),,"Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Netherlands,NED,Vaccine,Replicating viral vector,Pre-clinical,5/19/2020,Unknown,Newcastle disease virus vector (NDV-SARS-CoV-2/Spike),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Israel,ISR,Vaccine,Replicating viral vector,Pre-clinical,11/3/2020,Phase I/II expected to begin recruiting end of October 2020,VSV-S,NCT04608305,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
KU Leuven,Belgium,BEL,Vaccine,Replicating viral vector,Pre-clinical,5/4/2020,Unknown,Replicating viral vector; YF17D Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"The Lancaster University, UK",Great Britain,GBR,Vaccine,Replicating viral vector,Pre-clinical,5/19/2020,Unknown,Avian paramyxovirus vector (APMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy,China,CHN,Vaccine,Replicating viral vector,Pre-clinical,9/28/2020,Phase I expected to begin in Hong Kong in November 2020; Approved for clinical trials in September 2020,"Replicating viral vector, intranasal flu-based RBD (DelNS1-2019-nCoV-RBD-OPT1)",ChiCTR2000037782,Coalition for Epidemic Preparedness (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Tonix Pharma / Southern Research,United States,USA,Vaccine,Replicating viral vector,Pre-clinical,5/19/2020,Unknown,Replicating viral vector; horsepox vector expressing S protein; TNX-1800,,Unknown,,"Same platform as vaccine candidates for smallpox, monkeypox",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Manitoba,Canada,CAN,Vaccine,Replicating viral vector,Pre-clinical,11/9/2020,Unknown,Replicating VSV vector-based DC-targeting,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Western Ontario,Canada,CAN,Vaccine,Replicating viral vector,Pre-clinical,Prior to 4/20/2020,Unknown,Replicating viral vector; VSV-S,,Unknown,,"Same platform as vaccine candidates for HIV, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Wisconsin-Madison / FluGen/ Bharat Biotech,India,IND,Vaccine,Replicating viral vector,Pre-clinical,5/4/2020,Start Phase I trial in fall 2020,M2-deficient single replication (M2SR) influenza vector,,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Zydus Cadila Healthcare Limited,India,IND,Vaccine,Replicating viral vector,Pre-clinical,7/8/2020,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma,Germany,GER,Vaccine,RNA-based vaccine,Authorized,12/21/2020,"European Commission granted a ""conditional marketing authorisation"" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued ""emergency use authorization"" on 12/11/2020; Mexico COFEPRIS granted ""emergency use authorization"" on 12/11/2020; Saudi Food and Drug Authority (SFDA) ""approved the registration"" of the vaccine on 12/10/2020; Health Canada ""authorized"" on 12/9/2020; Bahrain granted ""emergency use authorization"" on 12/4/2020; U.K. MHRA granted ""temporary authorization for emergency use"" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020","3 LNP-mRNAs; BNT162 
","ChiCTR2000034825, EudraCT 2020-001038-36, NCT04368728, NCT04380701, NCT04523571, NCT04537949",Unknown,"Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1), Nature (https://www.nature.com/articles/s41586-020-2639-4), medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1), Nature (https://www.nature.com/articles/s41586-020-2814-7), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2027906?query=featured_home), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Moderna/ NIAID/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL,United States,USA,Vaccine,RNA-based vaccine,Authorized,12/18/2020,"U.S. FDA issued ""emergency use authorization"" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020",RNA; LNP-encapsulated mRNA (mRNA 1273),"NCT04283461, NCT04405076, NCT04470427",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),"Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2028436), Moderna (https://www.businesswire.com/news/home/20201116005608/en/Moderna%E2%80%99s-COVID-19-Vaccine-Candidate-Meets-Primary-Efficacy)",Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
CureVac,Germany,GER,Vaccine,RNA-based vaccine,Phase II,11/2/2020,"Phase IIb/III trial expected to begin by the end of 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020",RNA; mRNA (CVnCoV),"NCT04449276, NCT04515147",Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF),,"Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Arcturus/Duke-NUS/ Catalent
",United States,USA,Vaccine,RNA-based vaccine,Phase I/II,9/10/2020,Pre-clinical results released September 2020; Phase I/II began August 2020; Received approval to launch clinical trials in Singapore end of July 2020,LUNAR-COV19; RNA; mRNA,NCT04480957,Unknown,,Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Imperial College London/ VacEquity Global Health,Great Britain,GBR,Vaccine,RNA-based vaccine,Phase I/II,9/10/2020,Pre-clinical results published July 2020; Phase I/II trial began June 2020,RNA; LNP-nCoVsaRNA,ISRCTN17072692,UK Government,,"Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,China,CHN,Vaccine,RNA-based vaccine,Phase I,8/3/2020,Phase I trial began end of June 2020,mRNA (ARCoV),ChiCTR2000034112,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
BIOCAD,Russia,RUS,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Animal studies begin in April 2020,RNA; liposome-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
CanSino Biologics/Precision Nanosystems,China,CHN,Vaccine,RNA-based vaccine,Pre-clinical,5/21/2020,Unknown,RNA; mRNA lipid nanoparticle (mRNA-LNP),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Spain,ESP,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Unknown,RNA; Replicating defective SARS-CoV-2 derived RNAs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,United States,USA,Vaccine,RNA-based vaccine,Pre-clinical,6/17/2020,Unknown,"Self amplifying RNA, self-assembling delivery system",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
China CDC / Tongji University / Stermina,China,CHN,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Chula Vaccine Research Center/University of Pennsylvania,Thailand,THA,Vaccine,RNA-based vaccine,Pre-clinical,11/16/2020,Phase I expected to begin January 2021,LNP-mRNA; (ChulaCov19),NCT04566276,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science,Japan,JAP,Vaccine,RNA-based vaccine,Pre-clinical,8/31/2020,Clinical studies expected to begin March 2021,RNA; mRNA (DS-5670),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Elixirgen Therapeutics/ Fujita Health University,United States,USA,Vaccine,RNA-based vaccine,Pre-clinical,9/1/2020,"Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021",srRNA (EXG-5003),,Japan Agency for Medical Research and Development (AMED),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Belgium,BEL,Vaccine,RNA-based vaccine,Pre-clinical,5/4/2020,Start Phase I early 2021,RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Russia,RUS,Vaccine,RNA-based vaccine,Pre-clinical,8/31/2020,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,China,CHN,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,China,CHN,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
GeneOne Life Science / Houston Methodist,South Korea,KOR,Vaccine,RNA-based vaccine,Pre-clinical,Prior to 4/20/2020,Unknown,RNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Gennova,India,IND,Vaccine,RNA-based vaccine,Pre-clinical,7/15/2020,Unknown,"Self-amplifying
  RNA",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Globe Biotech Limited, Bangladesh",Bangladesh,BAN,Vaccine,RNA-based vaccine,Pre-clinical,11/9/2020,Unknown,D614G variant LNP-encapsulated mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Greenlight Biosciences
",United States,USA,Vaccine,RNA-based vaccine,Pre-clinical,5/12/2020,Unknown,"mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"IDIBAPS- Hospital Clinic, Spain",Spain,ESP,Vaccine,RNA-based vaccine,Pre-clinical,6/1/2020,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Infectious Disease Research Institute/ Amyris, Inc.",United States,USA,Vaccine,RNA-based vaccine,Pre-clinical,11/16/2020,Phase I expected to begin mid-2021,saRNA formulated in a NLC,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Max-Planck Institute of Colloids and Interfaces,Germany,GER,Vaccine,RNA-based vaccine,Pre-clinical,11/9/2020,Unknown,LNP-encapsulated mRNA encoding S,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"RNAimmune, Inc.",United States,USA,Vaccine,RNA-based vaccine,Pre-clinical,5/4/2020,Unknown,RNA; several mRNA candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Sanofi Pasteur / Translate Bio,France,FRA,Vaccine,RNA-based vaccine,Pre-clinical,10/15/2020,Phase I/II to start Q4 2020; Pre-clinical results released October 2020,"LNP-mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Selcuk University,Turkey,TUR,Vaccine,RNA-based vaccine,Pre-clinical,7/9/2020,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Ziphius Therapeutics/ Ghent University,Belgium,BEL,Vaccine,RNA-based vaccine,Pre-clinical,4/28/2020,Unknown,"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"SpyBiotech/
  Serum Institute of India",India,IND,Vaccine,Virus-like particle,Phase I/II,9/28/2020,Phase I/II began September 2020,Hepatitis B surface antigen (HBsAg) VLPs,ACTRN12620000817943,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Medicago Inc.,Canada,CAN,Vaccine,Virus-like particle,Phase I,12/14/2020,Phase II/III recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020,VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjs.,NCT04450004,Unknown,,"Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"ARTES Biotechnology
",Germany,GER,Vaccine,Virus-like particle,Pre-clinical,5/4/2020,Unknown,VLP; eVLP,,Unknown,,"Same platform as vaccine candidates for malaria
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Bezmialem Vakif University,Turkey,TUR,Vaccine,Virus-like particle,Pre-clinical,7/21/2020,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Doherty Institute,Australia,AUS,Vaccine,Virus-like particle,Pre-clinical,7/8/2020,Unknown,VLP; unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Icosavax,United States,USA,Vaccine,Virus-like particle,Pre-clinical,11/18/2020,Phase I expected to begin mid-2021; Pre-clinical results published October 2020,VLP displaying the SARS-CoV-2 receptor-binding domain (RBD); (IVX-411),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Imophoron Ltd / Bristol University's Max Planck Centre,Great Britain,GBR,Vaccine,Virus-like particle,Pre-clinical,Prior to 4/20/2020,Unknown,VLP; ADDomerTM multiepitope display,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Spain,ESP,Vaccine,Virus-like particle,Pre-clinical,6/23/2020,Unknown,S protein integrated in HIV VLPs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Thailand,THA,Vaccine,Virus-like particle,Pre-clinical,6/30/2020,Unknown,VLP + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Max-Planck Institute for Dynamics of Complex Technical Systems,Germany,GER,Vaccine,Virus-like particle,Pre-clinical,11/9/2020,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Medicago
  Inc./ GSK",Canada,CAN,Vaccine,Virus-like particle,Pre-clinical,7/14/2020,Unknown,VLP (CoVLP)+ Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Medicago Inc./ Dynavax,Canada,CAN,Vaccine,Virus-like particle,Pre-clinical,7/10/2020,Phase I to start mid-July 2020,VLP (CoVLP)+ Adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Middle East Technical University,Turkey,TUR,Vaccine,Virus-like particle,Pre-clinical,7/9/2020,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Navarrabiomed, Oncoimmunology group",Spain,ESP,Vaccine,Virus-like particle,Pre-clinical,6/1/2020,Unknown,"Virus-like particles, lentivirus, and baculovirus vehicles",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
OSIVAX,France,FRA,Vaccine,Virus-like particle,Pre-clinical,7/9/2020,Unknown,VLP (COVID-19 and SARS1),,European Innovation Council (EIC),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Saiba GmbH,Switzerland,SUI,Vaccine,Virus-like particle,Pre-clinical,Prior to 4/20/2020,Unknown,"VLP; virus-like particle, based on RBD displayed on virus-like particle",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Tampere University,Finland,FIN,Vaccine,Virus-like particle,Pre-clinical,11/9/2020,Unknown,VLPs produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Manitoba,Canada,CAN,Vaccine,Virus-like particle,Pre-clinical,11/9/2020,Unknown,Virus-like particle-based dendritic cell-targeting vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
University of Sao Paulo,Brazil,BRA,Vaccine,Virus-like particle,Pre-clinical,5/19/2020,Unknown,VLPs peptides/whole virus,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing,Canada,CAN,Vaccine,Virus-like particle,Pre-clinical,11/3/2020,Phase I/II trial expected to begin by end of 2020,"Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein (VBI-2900)",,Unknown,,"Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
AbVision,United States,USA,Vaccine,Unknown,Pre-clinical,5/13/2020,Unknown,AVI-205,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Adeleke University,Nigeria,NGR,Vaccine,Unknown,Pre-clinical,6/30/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Chile,CHI,Vaccine,Unknown,Pre-clinical,4/23/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Codiak BioSciences/ Ragon Institute,United States,USA,Vaccine,Unknown,Pre-clinical,6/4/2020,Unknown,exoVACC exome platform,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),United States,USA,Vaccine,Unknown,Pre-clinical,4/24/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,United States,USA,Vaccine,Unknown,Pre-clinical,4/21/2020,Animal study results by October 2020,"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",,Analog Devices Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
ISR Immune System Regulation,Sweden,SWE,Vaccine,Unknown,Pre-clinical,Prior to 4/20/2020,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
NidoVax,United States,USA,Vaccine,Unknown,Pre-clinical,6/18/2020,Unknown,unknown; IMT504 technology,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"Oragenics (Noachis Terra)/ Aragen Bioscience
",United States,USA,Vaccine,Unknown,Pre-clinical,9/28/2020,Phase I expected to start in early 2021,"TerraCoV2
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"OSE
  Immunotherapeutics",France,FRA,Vaccine,Unknown,Pre-clinical,11/9/2020,"Clinical
  trials expected to begin end of 2020/early 2021; Pre-clinical results
  released in August 2020",T cell-based vaccine platform (CoVepiT),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Precision Vaccines Program at Boston Children's Hospital,United States,USA,Vaccine,Unknown,Pre-clinical,Prior to 4/20/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Shenzhen Geno-Immune Medical Institute,China,CHN,Vaccine,Unknown,Pre-clinical,5/12/2020,Unknown,Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins,NCT04299724,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Shenzhen Geno-Immune Medical Institute,China,CHN,Vaccine,Unknown,Pre-clinical,5/12/2020,Unknown,LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes,NCT04276896,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
SK Biosciences,United States,USA,Vaccine,Unknown,Pre-clinical,Prior to 4/20/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Tulane University,United States,USA,Vaccine,Unknown,Pre-clinical,Prior to 4/20/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"United
  Biomedical (UBI)/ c19",United States,USA,Vaccine,Unknown,Pre-clinical,9/2/2020,,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vault Pharma/ University of California Los Angeles,United States,USA,Vaccine,Unknown,Pre-clinical,6/17/2020,Unknown,nanoparticles (vaults) as second-line defense of infection,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vir Biotechnology / GSK,United States,USA,Vaccine,Unknown,Pre-clinical,Prior to 4/20/2020,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Vivaldi Biosciences/ Esco Aster Pte Ltd,United States,USA,Vaccine,Unknown,Pre-clinical,6/2/2020,Unknown,Chimeric vaccine (coronavirus and influenza),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Peru,PER,Vaccine,Replicating bacterial vector,Pre-clinical,8/28/2020,Unknown,Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
"University of California, Los Angeles (Horwitz Lab)",United States,USA,Vaccine,Replicating bacterial vector,Pre-clinical,5/10/2020,Unknown,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens,,Unknown,,Same platform as vaccines against select agents and emerging pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit
